The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone
1998

Treatment of Nephrotic Syndrome with VAD Chemotherapy

Sample size: 11 publication Evidence: moderate

Author Information

Author(s): AM Wardley, GC Jayson, DJA Goldsmith, MC Venning, P Ackrill, JH Scarff

Primary Institution: Christie Hospital

Hypothesis

Can vincristine, doxorubicin, and dexamethasone (VAD) effectively treat nephrotic syndrome caused by primary amyloid?

Conclusion

Three out of four patients treated with VAD achieved a partial response and are alive in remission after several years.

Supporting Evidence

  • Three out of four patients treated with VAD achieved a partial response.
  • Patients treated with VAD had a median survival of 64.5 months.
  • Those receiving supportive care had a median survival of only 11.7 months.

Takeaway

Doctors used a special medicine to help sick patients, and most of them got better and are still okay years later.

Methodology

Retrospective analysis of patients with biopsy-proven AL and nephrotic syndrome treated at Christie Hospital from 1985 to 1996.

Potential Biases

Differences in patient characteristics between treatment groups may introduce bias.

Limitations

The study is preliminary and not randomized, which may affect the reliability of the results.

Participant Demographics

Patients included both males and females with varying ages and performance statuses.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication